P Bousquet’s research while affiliated with University of Strasbourg and other places

What is this page?


This page lists works of an author who doesn't have a ResearchGate profile or hasn't added the works to their profile yet. It is automatically generated from public (personal) data to further our legitimate goal of comprehensive and accurate scientific recordkeeping. If you are this author and want this page removed, please let us know.

Publications (108)


Protective effects of a new AMPK activator, LNP599, in a marmoset model of diet-induced obesity and dyslipidemia
  • Article

May 2021

·

23 Reads

Archives of Cardiovascular Diseases Supplements

·

M. Weiss

·

·

[...]

·

Introduction Obesity is an undoubtable risk factor for metabolic and cardiovascular diseases and significantly contributes to the global morbi-mortality. We previously reported that LNP599, an imidazoline-like activator of hepatic AMPK/adiponectin signaling, protects against the development of obesity and associated cardio-metabolic disorders in rats. LNP599 may therefore be a suitable drug candidate for a therapeutic approach targeting the development of obesity at very early stages. Objective The objective was to evaluate the effects of LNP599 in a model of diet-induced overweight and metabolic disorders in a nonhuman primate, the common marmoset (Callithrix jacchus), and particularly to establish the impact of the compound on cholesterol homeostasis, i.e., HDL and LDL/VLDL lipoproteins. Method Marmosets were fed normal or hypercaloric chow during 16 weeks. Diet-induced changes in body weight and metabolism were assessed. Effects of LNP599 were evaluated in a subset of animals receiving the compound at a daily dose of 10 mg/kg over the 16 weeks. Results Hypercaloric chow induced significant overweight associated with a marked dyslipidemia: hypertriglyceridemia (+63%), hypercholesterolemia (+56%) and reduced HDL over LDL/VLDL cholesterol ratio (−24%). LNP599 blunted the diet-induced body weight gain and largely protected against the development of hypertriglyceridemia (+33%). Total cholesterol was unchanged but the ratio of HDL over LDL/VLDL cholesterol was more than doubled (≈2 in LNP599-treated animals vs. ≈0.9 in untreated marmosets). Conclusion Marmosets receiving the enriched diet represent a highly clinically relevant experimental model to study the pathophysiology of obesity and related dyslipidemia and to evaluate the effects of emerging therapies targeting these disorders. Our data confirm the preventing effects of LNP599 in this nonhuman primate model and demonstrate for the first time the high potency of this drug in promoting HDL-cholesterol.



Expression of muscarinic receptors in adults and children with severe vagal syncope

January 2018

·

12 Reads

Archives of Cardiovascular Diseases Supplements

Syncope is an ordinary reason for consultation in cardiac units. Vagal etiology is frequently mentioned but many additional tests are often proposed to exclude other causes. Overexpression of muscarinic M2 receptors (M2R) was observed in the myocardium and blood of a model of rabbits with vagal hyperreactivity, then in the hearts of newborns deceased from sudden infant death syndrome and recently in the blood of infants who experienced severe idiopathic apparent life threatening events (iALTE). We investigated M2R and acetylcholinesterase (AchE) expressions in the blood of adults and children who experienced severe vagal syncope. Method A total of 151 subjects were prospectively enrolled in a multicenter, comparative study. Fifty-five adults and 43 children ages 1 to 18, exhibiting severe and repeated vagal syncope, were compared to 53 healthy matched controls. Total mRNA was blindly extracted from all blood samples and reverse transcribed into cDNA. M2R and AchE expressions were measured by RT-qPCR. Results M2R expression was distinctively higher in the vagal group (n = 98) as compared to controls (n = 53) (median 0.923 vs. 0.238, P = 0.0006). Similarly AchE level was higher in the vagal group than in controls (median 0.796 vs. 0.423, P = 0.0078). Perforce, the ratio M2R/AchE was strongly higher in the vagal group than in controls (median 1.083 vs. 0.79, P = 0.0056). Conclusion M2R and AchE overexpression was shown in the blood of adults and children exhibiting severe vagal syncope compared to controls. AchE overexpression seems to an adaptive reaction, not fully mature in children. M2R overexpression could be a simple blood biomarker of vagal syncope and help in the assessment of faintness. Further, these results may suggest a continuum between iALTE in infants and vagal syncope in both children and adults, with a muscarinic common feature. Larger studies are needed to confirm this biomarker's potential and to evaluate the clinical implications.









Citations (44)


... Perhaps the most likely of these to be involved is the AIRP antiserum detected 43-kDa imidazoline receptor candidate from human RVLM ( Greney et al., 1994) since it has been put forward as a prime candidate for I 1 imidazo line receptors ( Vonthron et al., 1998). It is known to inhibit 3 H-clonidine labeled imidazoline binding sites ( Dontenwill et al., 1999). ...

Reference:

Contribution of imidazoline receptors and α2-adrenoceptors in the rostral ventrolateral medulla to sympathetic baroreflex inhibition by systemic rilmenidine
Molecular characterization of human cerebral I-1 imidazoline receptor
  • Citing Article
  • January 1998

Naunyn-Schmiedeberg's Archives of Pharmacology

... In this context, centrally acting antihypertensive drugs, which modulate central sympathetic activity, may be attractive drugs for MS treatment by modulating sympathetic overactivity directly in the central nervous system [25]. This pharmacological group that is represented by clonidine and related compounds with high affinity for a 2 Rs and/or I 1 Rs has potent antihypertensive effects by reducing sympatho-excitatory inputs in the brainstem by activating a 2 Rs in particular within the RVLM [10]. The second generation of centrally acting antihypertensive drugs including rilmenidine and moxonidine, which have higher selectivity for I 1 Rs, is characterized by reduced central side effects such as dizziness and daytime sedation [10,53]. ...

Participation of Imidazoline Receptors and Alpha2--Adrenoceptors in the Central Hypotensive Effects of Imidazoline-Like Drugs
  • Citing Article
  • June 1999

Annals of the New York Academy of Sciences

... Određivanje afiniteta vezivanja liganda za I 1 -IR je vršeno primenom metode kompetitivne inhibicije vezivanja radioliganda, kao što su [ [25][26][27][28], na plazma membranama ćelija centralnog dela nadbubrežne žlezde (chromaffin cells) [21,22,29], na plazma membranama ćelija neuroendokrinog tumora chromaffin ćelija (rat pheochromocytoma cells (PC 12)) [23,24,[30][31][32][33], plazma membranama humanih trombocita [34] i plazma membranama ćelija prostate psa [35]. ...

Identification of Human I1 Receptors and Their Relationship to α2‐Adrenoceptors
  • Citing Article
  • June 1999

... [13][14][15] The nonadrenergic component of the central hypotension induced by imidazoline-like drugs was afterward attributed to their ability to act at specific binding sites, insensitive to catecholamines, called imidazoline binding sites (IBS) and located in the NRL/RVLM region. 16,17 Because relevant animal models and ligands selective for these nonadrenergic sites over ␣ 2 ARs were lacking, it was impossible to clarify how (in the case that these 2 mechanisms should work together) they might affect BP regulation and also how they might account for the overall hypotensive action of imidazoline-like drugs. It may be interesting to note that after central injection, the onset of the hypotensive effect of these drugs is much faster than that of ␣-MNA. ...

Imidazoline receptors: An update
  • Citing Article
  • December 1996

Pharmacochemistry Library

... Until today three subtypes of imidazoline receptors, I1-IR, I2-IR, and I3-IR, were experimentally characterized (6,7). The I1-IRs were defined as one of the binding sites involved in the control of blood pressure (8). The I1-IRs have high affinity for clonidine, moxonidine, and rilmenidine, while the I2-IRs has high affinity for idazoxan and its analogues (9,10). ...

From the α2-adrenoceptors to the imidazoline preferring receptors
  • Citing Article
  • December 1992

Fundamental and Clinical Pharmacology

... On this basis, a possible role of I 1 -R in pain modulation can be theoretically suggested although so far unexplored. In the present work we studied the effects of I 1 -R modulation against oxaliplatin-induced neuropathic pain by using the selective I 1 -R agonist compound 2 (in this paper named carbophenyline, highly selective over I 2 , α 2 , and 5-HT 1A receptors [30,31]) (Fig. 1). Its effects on pain threshold were evaluated after single or repeated administrations in the absence or presence of the I 1 -R antagonist 3 [2-(1-methyl-2phenylethyl)-4,5-dihydro-1H-imidazole] (Fig. 1) [32], highly selective over I 2 , α 2 and 5-HT 1A receptor and the well-known I 1 /α 2 receptor antagonist efaroxan [33] which proved to be selective over several other biological targets [33; https:// pubchem.ncbi.nlm.nih.gov/compound/Efaroxan#section= ...

Rational Design of the New Antihypertensive I1-Receptor Ligand 2-(2- Biphenyl-2-yl-1-methyl-ethyl)-4,5-dihydro-1H-imidazole
  • Citing Article
  • December 2005

Letters in Drug Design & Discovery

... ; https://doi.org/10.1101/2021.09.29.462492 doi: bioRxiv preprint optical process that two photons are combined to form a new photon with twice the energy, which efficiently occurs in noncentrosymmetric molecules such as the collagen in biological tissue enabling a visualization of collagen without additional labeling(Mostaco-Guidolin, Rosin et al., 2017, Zipfel, Williams et al., 2003. A label-free SHG imaging have been widely used to monitor the fibrillar collagen in specimens of various fibrotic diseases in skin (Chen, Chen et al., 2009), liver (Goh, Leow et al., 2019), lung (Kottmann, Sharp et al., 2015), carotid artery (Megens, oude Egbrink et al., 2008), eye (Tan, Sun et al., 2007), tendon and ligaments (Doras, Taupier et al., 2011). In brain tissue, SHG imaging was used to investigate the structure and polarity of microtubules in neuronal processes (Dombeck, Kasischke et al., 2003, Van Steenbergen, Boesmans et al., 2019, and collagen deposition in glioblastoma (Jiang, Wang et al., 2017). ...

Polarization state studies in second harmonic generation signals to trace atherosclerosis lesions
  • Citing Article
  • Full-text available
  • July 2011

... Clonidine activates the postsynaptic alpha2-adrenergic receptors of the vasomotor centers, reduces conduction of sympathetic impulses to the heart and blood vessels, which leads to a decrease in cardiac output, heart rate and peripheral vascular resistance. Clonidine penetrates the blood brain barrier and affects the reticular formation, which is manifested by the sedative effect of the drug (Bousquet et al. 1992). Serious or mild overdose of naphazoline induces a similar mechanism of action, stimulating the same receptors as clonidine, and causes a similar effect. ...

[Pharmacology of imidazoline receptors and cardiovascular regulation. Imidazoline receptors and blood pressure]
  • Citing Article
  • December 1992

Thérapie

... These authors provided evidence that in hypertensive subjects, administration of betablockers potentiates daily life baroreceptor control of HR and that this occurs uniformly throughout the different behavioral conditions. A special mention can be made of the specific imidazoline sensitive binding sites insensitive to catecholamines, which are present in the nucleus reticularis lateralis [70]. The main effect of acute dosing of 1 mg of rilmenidine was a reduction of blood pressure and HR variability in the standing position [71]. ...

From the alpha 2-adrenoceptors to the imidazoline preferring receptors
  • Citing Article
  • February 1992

Fundamental and Clinical Pharmacology